FDA approves apalutamide for castration-resistant prostate cancer.
Lisa M. Holle, PharmD, BCOP, FHOPA
Emicizumab-kxwh brings together factors IXa and X to restore the function of the missing activated factor VIII and the blood clotting process.
A new era of treatment has arrived—here’s what you need to know.
The New Drug Review for April
CONTINUING PHARMACY EDUCATION
Here: an overview of atezolizumab, the first new drug in two decades for bladder cancer and now approved for NSCLC.
New drug review
FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.